VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma - Siegel, David S.; Goldschmidt, Hartmut (Clinical lymphoma, myeloma & leukemia, 2016)
Gesehen am 08.08.2019